Disease · MONDO_0002203
Comparisons in its trials71
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 71
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide | 14 of 224 | 111 of 2,146 | 2,370 | NCT01919697 | Trial comparisons |
| Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) | 123 of 224 | 620 of 2,146 | 2,370 | NCT01919697 | Trial comparisons |
| Plecanatide 3 mg vs Plecantide 6 mg: Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline | 192 of 224 | 1,498 of 2,146 | 2,370 | NCT01919697 | Trial comparisons |
| Plecanatide 3 mg vs Plecanatide 6 mg: deaths from any cause | 0 of 224 | 1 of 2,146 | 2,370 | NCT01919697 | Trial comparisons |
| Plecanatide 3 mg vs Plecanatide 6 mg: serious adverse events | 8 of 224 | 32 of 2,146 | 2,370 | NCT01919697 | Trial comparisons |
| CB-5945 vs Placebo: serious adverse events | 40 of 703 | 36 of 700 | 1,403 | NCT01696643 | Trial comparisons |
| Naldemedine vs Placebo: serious adverse events | 60 of 621 | 73 of 619 | 1,240 | NCT01965652 | Trial comparisons |
| LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): deaths from any cause | 1 of 508 | 0 of 318 | 826 | NCT02590432 | Trial comparisons |
| LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): serious adverse events | 16 of 508 | 6 of 318 | 826 | NCT02590432 | Trial comparisons |
| LINZESS® 145 μg (CIC, Open Label) vs LINZESS® 290 μg (IBS-C, Open Label): Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in Serum | 3 of 498 | 1 of 309 | 807 | NCT02590432 | Trial comparisons |
| NKTR-118 25 mg vs Usual Care: Incidence of Patients Experiencing Severe Adverse Events (SAEs) | 51 of 534 | 30 of 270 | 804 | NCT01336205 | Trial comparisons |
| NKTR-118 25 mg vs Usual Care: Incidence of Patients Experiencing at Least One Adverse Event (AE) | 437 of 534 | 195 of 270 | 804 | NCT01336205 | Trial comparisons |
| NKTR-118 25 mg vs Usual Care: serious adverse events | 51 of 534 | 30 of 270 | 804 | NCT01336205 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Abdominal Pain Response for 9 Out of 12 Weeks | 105 of 293 | 80 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks | 121 of 293 | 93 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Response for 13 Out of 26 Weeks | 104 of 293 | 73 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 6 Out of 12 Weeks | 139 of 293 | 100 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 9 Out of 12 Weeks | 65 of 293 | 18 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Response for 6 Out of 12 Weeks | 107 of 293 | 71 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Abdominal Pain Response for 6 Out of 12 Weeks | 146 of 293 | 115 of 300 | 593 | NCT02686138 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002203/comparisons